Jaguar8 commented on a stock · Jul 12, 2024 06:10

NEWS

Annexon to Present Additional Phase 2 Data Showing Preservation of Visual Function and Structure by ANX007 in Geographic Atrophy at the 42nd ASRS Annual Scientific Meeting

Annexon will present additional data from its Phase 2 ARCHER trial on ANX007 at the 42nd ASRS Annual Scientific Meeting in Stockholm, Sweden from July 17-20, 2024. The presentations will highlight the protective effects of ANX007 on visual acuity and anatomical measures in patients with geographic atrophy (GA), a condition causing irreversible vision loss. Dr. Glenn J. Jaffe and Dr. Joel Pearlman will discuss the trial's findings, showcasing ANX007's impact on the central macula's ellipsoid zone and retinal pigment epithelium. This trial is important for advancing therapies for neuroinflammatory diseases affecting vision.

Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more

Translate

Report

8618 Views

Comment

Jaguar8

Spread kindness and love. Life is short. Don’t let greed eat you.

6184

Followers

Following

66K

Visitors